






































Orofacial signs and dental abnormalities in
patients with Mulvihill–Smith syndrome
A literature review on this rare progeroid pathology
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Abstract
Background: Mulvihill–Smith syndrome is a rare sporadic condition that was first recognized in 1975. A total of 11 cases have
been described in the literature. The aim of this study was to describe the orofacial signs and dental anomalies, their frequency, and
the relationship between Mulvihill–Smith syndrome and other progeroid syndromes via a review of the literature.
Methods: A systematic PubMed search was performed to retrieve articles published between 1975 and the present day that
described patients affected by Mulvihill–Smith syndrome. The search identified 14 articles, and data on 11 patients were extracted
from the selected articles.
Results: A total of 7 patients (63.6%) affected by Mulvihill–Smith syndrome were described as having a typical “bird” face. Dental
abnormalities, including irregular shape, enamel defects, hypodontia, and taurodontism, were described in 6 patients (54.5%). All
patients (100%) had multiple pigmented nevi on the face and a lack or thinning of subcutaneous tissue around the neck and face.
Three patients with Mulvihill–Smith syndrome exhibited early onset of tumors of the gastrointestinal tract, including the tongue.
Conclusion: Mulvihill–Smith syndrome is a clinically complex disease that may be caused by a single gene mutation. Numerous
different tissues of the body are affected. This analysis of the orofacial signs may help clinicians to diagnose this rare pathology.
Abbreviations: Ig = immunoglobulin, OMIM = Online Mendelian Inheritance in Man, PRNP gene = Prion protein gene, UV =
ultraviolet.
Keywords: dental abnormalities, management progerodi syndrome, Mulvihill-Smith syndrome, oro-facial signs, progerian
pathology, rare disease
1. Introduction
Aging and death are unavoidable events in the life cycle of an
organism. In recent decades, researchers have given consider-
able attention to the physiological events and underlying
biological processes that are involved in aging.[1] Aging is a
consequence of nuclear metabolic defects that promote the
accumulation of mutations and chromosomal anomalies and
lead to macromolecule and DNA damage.[1,2] Due to the
features of premature aging, the rare progeroid syndromes have
attracted much attention.[3]
In 1975, Mulvihill and Smith reported a case entitled
“Another disorder with prenatal shortness of stature and
premature aging,” which described a 17-year-old male with a
mild intellectual disability, microcephaly, very short stature,
hypodontia, numerous pigmented nevi and freckles, chronic
infections, and insulin dependent diabetes mellitus.[4] Since the
recognition of this syndrome, 11 patients have been reported.[4–
14] Mulvihill–Smith syndrome is a rare genetic disorder [Online
Mendelian Inheritance in Man (OMIM) number: %176690]
that is characterized by a progeria-like phenotype.[12] Its
inheritance mode is likely to be autosomal recessive, as the
syndrome affects females and males and those born to
consanguineous parents[9,14]; however, the causative gene has
not yet been identified.[5] The first cases reported by Mulvihill
and Smith,[4] Elliott,[6] and Baraitser et al[8] described isolated
male patients with no parental consanguinity; however, in
1993, Ohashi et al[9] reported the case of a 30-year-old
Japanese woman who was immunodeficient and whose parents
were first cousins. They suggested autosomal recessive inheri-
tance of the pathology in this patient and indicated that the
female patient described in 1979 by Wong et al[7] might have
been affected by the same syndrome.[9] In 1994, Bartsch et al[10]
reported another male patient with Mulvihill–Smith syndrome
and immunodeficiency, while de Silva et al[11] described the
seventh case of Mulvihill–Smith progeria-like syndrome in a 5-
year-old boy in 1997. The mutation responsible for this
syndrome was not identified due to its rarity and the diagnosis
was therefore purely clinical.[12] A total of 30 progeroid
syndromes are currently known, including Ehlers–Danlos
syndrome (OMIM number: #130070), progeroid syndrome
neonatal (OMIM number: %264090), Werner syndrome
(OMIM number: #277700), Cockayne syndrome A (OMIM
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number: #216400), Nestor–Guillermo progeria syndrome
(OMIM number: #614008), and Hutchinson–Gilford progeria
syndrome (OMIM number: #176670). The progeroid syn-
dromes are characterized by signs of premature aging,
including alopecia, decreased subcutaneous fat, skin pigmenta-
tion, dry and wrinkled skin, hypogonadism, and clinical and
laboratory findings that indicate a decline in cellular and
humoral immunocompetence.[9]
The first mention of progeria in the medical literature was
reported in the case of a 3-year-old boy in 1886 by Hutchinson,[2]
who suggested that this disorder was a type of ectodermal
dysplasia. Hutchinson[2] described a second patient in 1895;
however, this casewasexplained inmoredetail byGilfordwhohad
taken care of the patient for 17years.[1–3]Gilfordfirst used the term
progeria for this disease: “pro” meaning before and “geras”
meaning old age in AncientGreek.[15] Progeroid syndromes have a
very low incidence rate of one per 8 million live births.[16] Like
other accelerated aging diseases, they are caused bydamagedDNA
repair.[17] Approximately 100 cases have been recognized in the
literature.[18] Patients affected by this disorder normally live for 13
years; however, many have been described to live into their late
teens and early 20s but very few reach their 40s.[19,20] The causes of
death in individuals with this lethal premature aging disease are
stroke or myocardial infarction.[21]
The signs and symptoms reported in the 11 cases of Mulvihill–
Smith syndrome include short stature, microcephaly, pigmented
nevi, loud and raucous voice, increased facial fat, hypertelorism,
alopecia, brachydactyly, genital anomalies, visual change, hypo-
spadias, diabetes, recurrent infections, deafness, tumor develop-
ment (e.g., gastric, tongue, pancreas, and melanoma), intellectual
disability, sleep disorders, hepatic dysfunction, and orofacial and
dental abnormalities. Childrenwith progeroid disorders are at risk
of serious oral complications and require an evaluation by an oral
specialist at the time of diagnosis. They are also at risk of serious
ophthalmic complications due to ocular surface disease.[1] Some
reported ophthalmological findings in patients affected by
Mulvihill–Smith syndrome include myopia, amblyopia, astigma-
tism, dry eye disease, meibomian gland dysfunction, allergic
conjunctivitis, band keratopathy, keratoconus, endothelial dys-
trophy, cataracts, and retinal abnormalities.[22]
This article aims to review the findings concerning the clinical
features of Mulvihill–Smith syndrome, particularly the orofacial
and dental abnormalities, their frequency, and the relationship
between Mulvihill–Smith syndrome and other progeroid syn-
dromes, to define which clinical features permit the distinction
between Mulvihill–Smith syndrome and other better known
progeroid syndromes.
2. Patients and methods
A systematic PubMed search was performed to retrieve articles
published between 1975 and the current day that described
patients affected by Mulvihill–Smith syndrome. The search
strategy included the combination of 3 keywords: Mulvihill–
Smith, Mulvihill–Smith syndrome, and progeroid disorder. This
was completed with a manual search of the reference lists of the
selected studies. Only articles that provided a clinical description
of the case were included.
As this is a literature review, it was granted exemption in
writing by the institutional review board of the Catholic
University of Sacred Heart, Rome. The Declaration of Helsinki
guidelines were followed in this investigation.
The search identified 43 articles, 14 of which described
Mulvihill–Smith cases. Three articles did not describe a new case,
while 11 articles described unique cases. The first case was
described in 1975[4] and the last in 2011.[14] Seven of the patients
were male and 4 were female, and the median age of the subjects
was 17 years (range: 4–30). The demographic features of the
study population are reported in Table 1.
3. Results
Seven of the 11 patients (63.6%) affected by Mulvihill–Smith
syndrome were described as having a typical “pinched” or
“bird” face that was characterized by hypoplasia of the lower
half of the face (micro- or retrognathia). The lack or thinning of
subcutaneous tissue around the neck and face was reported in
all (100%) patients. Mild hypertelorism was present in 6
patients (54.5%), while all patients (100%) had multiple
pigmented nevi on the face. Dental abnormalities such as
irregular shape, enamel defects, hypodontia, and taurodontism
were described in 6 patients (54.5%). A bifid uvula was
reported in 1 patient (9.1%).
Table 1
Orofacial signs in the 11 patients.
Patient 1
Patient 2





















Year 1975 1975 1979 1988 1993 1994 1997 2005 2009 2010 2011
Sex M M F M F M M F F M M
Age, y 17 5 7 14 30 20 4 25 28 16 24
Bird face     /   /  NR NR
Lack of facial
subcutaneous fat
          




    /  / NR NR NR 
Micro- or retrognathia     /    NR NR NR
Pigmented nevi           
Tongue tumor / / / / / / /   / /
Bifid uvula / / / / / / / /  / /
F= female; M=male; NR=nonreported; x= yes; /=no.
Passarelli et al. Medicine (2018) 97:18 Medicine
2
The third reported case of Mulvihill–Smith syndrome was
described in 1979 by Wong et al.[7] The 14-year-old female
patient had a triangular face with central cutaneous atrophy,
reduced lower facial height, and micrognathia. Intraoral and
radiographic examinations revealed oligodontia, incomplete
dental root development, protruding maxillary central incisors,
periodontitis, and reduced alveolar bone height. No development
of the adenoids and tonsils was observed.[7]
Ohashi et al[9] reported that their patient’s teeth first erupted at
7 months and developed in normal alignment but were mostly
lost as a consequence of severe caries.
Orofacial anddental situations in the sixthpatientwere carefully
described by Bartsch et al.[10] The patient had malpositioned,
hypoplastic deciduous, and permanent teethwith enamel defects; a
narrow and highly arched palate; malocclusion (overbite); and
micrognathia. In addition, the second premolars and lower third
molars were absent (hypodontia), the upper lateral incisors were
cone-shaped, the molars had enlarged coronal pulp and reduced
roots (hypotaurodontism), and the lower first molars and upper
third molars were tilted forwards.[10]
The eighth patient, described by Ferri et al in 2005,[12]
underwent surgical removal of the left part of her tongue because
of the occurrence of a squamous cell carcinoma when she was 22
years old. Another female patient with Mulvihill–Smith syn-
drome underwent surgical removal of a tongue tumor at age 27
years. In this case, the histopathologic diagnosis was an ulcer of
the tongue with chronic inflammation; however, no evidence of
malignancy was disclosed.[5] Agenesis of the second premolars
and the right maxillary central incisors and poor oral health
condition were reported in the eleventh case of Mulvihill–Smith
syndrome in the literature.[14]
4. Discussion
Mulvihill–Smith syndrome is a clinically complex disease that
may be caused by a single gene mutation. The disorder affects
numerous different tissues of the body.[14] In their subject with
Mulvihill–Smith syndrome, Ferri et al[12] reported an absence of
chromosomal abnormalities and that the karyotype was normal.
Therefore, they suggested that a new mutation could be the
genetic cause of this syndrome. Since the first report of a 17-year-
old boy with prenatal short stature, a pinched face, premature
aging, multiple pigmented nevi, intellectual disability, photosen-
sitivity, thin skin, sparse hair, and oligodontia was reported in
1975, 10 other patients with Mulvihill–Smith syndrome have
been identified.[4–14]Table 1 provides a summary of the orofacial
signs described in the 11 reported cases in the literature. The
presence of rhinitis, allergic conjunctivitis, and recurrent
infections associated with low levels of immunoglobulins and
T- and B-cells in almost all cases strengthens the idea that
immunodeficiency is one of the characteristics of the syn-
drome.[10,23] There is currently no known gene responsible for
Mulvihill–Smith syndrome; however, considering that the genetic
causes of many other progeroid syndromes have been discovered,
it is pertinent to determine whether any of the previously reported
patients may actually suffer from a different progeroid syndrome
with a somewhat atypical presentation. Previous authors
diagnosed their patients with Mulvihill–Smith syndrome based
on phenotypical (e.g., facial features and pigmented nevi) and
pathological aspects.[9–11] For example, Ohashi et al[9] reported
that their patient presented with a possible manifestation of
Werner syndrome (another premature aging disease) due to the
short stature and hypogonadism; however, they excluded this
diagnosis, as patients with Werner syndrome are usually of
normal intelligence and do not show signs of immunodeficiency.
4.1. Dental abnormalities
Wong et al[7] suggested that oligodontia, alveolar and dental
development deficiency, and periodontitis further contributed to
reduced facial height in patients with Mulvihill–Smith syndrome.
De Silva et al[11] underlined the association between taurodont-
ism, which results from delayed development of Hertwig– Bruhn
epithelial division between the dental roots, and autosomal
dominant inheritance of Klinefelter syndrome and suggested the
trait be used as a diagnostic feature in future cases. Gebin
observed that a high-pitched voice in 8 of the cases may be a
reflection of the abnormal face structure.[14]
4.2. Tumors of the gastrointestinal tract
Three patients with Mulvihill–Smith syndrome were diagnosed
with early-onset tumors of the gastrointestinal tract: a 23-year-old
patient had a signet ring cell carcinoma of the stomach,[10] a 20-
year-old patient had a squamous cell carcinoma of the tongue,[12]
and a 17-year-old patient had a solid pseudopapillary cystic tumor
of the pancreas.[5] Yagihashi et al[5] suggested that early-onset
tumors could represent an important adult Mulvihill–Smith
syndrome phenotype that requires attention and that patients
with Mulvihill–Smith syndrome may be susceptible to specific
types of gastrointestinal tract tumors. Although histological
examination by Yagihashi et al[5] did not reveal tumor cells in
the abnormal tongue mass, Ferri et al[12] reported a possible
increased risk ofMulvihill–Smith syndrome in patients developing
squamous cell carcinoma of the tongue or oral mucosa.
4.3. Pigmented nevi
Multiple pigmented nevi is a typical feature of Mulvihill–Smith
syndrome; however, it also occurs in a large number of genetic
immunodeficiency syndromes such as N syndrome (OMIM
number: 310465), Fanconi pancytopenia (OMIM number:
#22765), and Maraschio–Peretti type chromosomal instability.
Heyne et al[24] described junctional-type nevus cell nevi after
leukemia therapy in a monozygotic twin; in this case, the possible
mutagenic effects of cytostatic therapy on somatic cells in a state
of induced immunoincompetence were considered.[10] Thus,
Bartsch et al[7] suggested that immunodeficiency and nevi are
possibly related to Mulvihill–Smith syndrome.
4.4. Orofacial signs in other progeroid syndromes
Other progeroid syndromes have many facial characteristics in
common with Mulvihill–Smith syndrome, including loss of
subcutaneous fat; a convex nasal ridge; a narrow, compressed,
and deformed point of the nose; a small chin; prominent outer
ears that lack lobules; and anatomical eye deformation. Almost
all children have a highly pitched voice and normally speak quite
well, and a mild conductive loss was reported in the majority of
European patients.[2,21,25,26]
The loss of subcutaneous fat generally starts at 6 months of age
but becomes more visible at 3 or 4 years of age. This loss of
subcutaneous fat first becomes visible in the limbs and thorax, then
the face and buccal, and it finally disappears in the pubic area;
almost all children with progeroid syndromes have a prominent
belly due to intraabdominal fat. Prominent appearance of the eyes,
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thin skin, and easily visible blood vessels are caused by the
vanishing intraorbital andsubcutaneous fat; skin appearswrinkled
in themoutharea. Elevated collagen type IVand elastinproduction
are recognized as the cause of the skin irregularity.[2,26,27] Caries
and periodontal pathology affect patients suffering from Mulvi-
hill–Smith syndrome and other progeroid syndromes. Of the oro-
dental abnormalities, hypodontia and taurodontism were most
commonly described in Mulvihill–Smith syndrome. Conversely,
patients suffering from other progeroid syndromes reported
ankyloglossia, an ogival palate, vertical chewing where rotatory
chewing is supposed to develop, delayed tooth eruption, irregular
teeth showing elevated decay due to maxilla dental crowding,
limitedmandible size, and hard dental care caused by aminute oral
aperture. Poor compliance is also seen inpatientswhoare normally
jovial, agile, and with normal psychosocial growth.[1] The typical
orofacial signs in other progeroid syndromes andMulvihill–Smith
syndrome are reported in Table 2.
4.5. Ophthalmological findings
The reported ophthalmological findings in the 11 patients with
Mulvihill–Smith syndrome include astigmatism, myopia, endo-
thelial dystrophy, keratoconus, cataracts, amblyopia, and allergic
conjunctivitis. Irahim et al analyzed ocular complications in a
Japanese patient and described new ophthalmic features,
including band keratopathy, meibomian glands dysfunction,
posterior subcapsular cataracts, and dry eye disease. The authors
also proposed oxidative stress disorder due to low manganese
superoxide dismutase levels as an explanation for the aging
manifestation of Mulvihill–Smith syndrome.[28] Tyagi et al[22]
described retinal features in a 25-year-old man with Mulvihill–
Smith syndrome. The authors stated that Mulvihill–Smith
syndrome showed phenotypic similarities with other progeroid
syndromes such as Cockayne syndrome, which exhibits
pigmentary retinopathy and characteristic electrodiagnostic
changes; however, the functional electroretinography changes
and the absence of fundus pigmentation suggest a different
underlying pathophysiology. Other described retinal features
included schisis, diffuse thickening, and folding of the retinal
layers in both eyes. The authors reported that structural changes
in the retina were progressive with loss of foveal contours and
wrinkling of the inner retinal layers.[22]
4.6. Lipid disorders
Bartsch et al[7] andWong et al[10] described hypercholesterolemia
in patients suffering from Mulvihill–Smith syndrome. It is well
known that lipid metabolism disorders are common in progeroid
Table 2
Typical orofacial signs in some progeroid syndromes.
Syndrome
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syndromes such as Hutchinson–Gilford progeria; however,
further analysis is required to establish whether hypercholester-
olemia represents a typical manifestation of Mulvihill–Smith
syndrome.
4.7. Anesthetic difficulties
A few papers have discussed the anesthetic management in
patients with progeroid disorders. Stevic et al[29] underlined that
the anesthetic management and positioning of patients with
Mulvihill–Smith syndrome may be difficult due to bone
deformities, arthritic joint changes, and atherosclerosis. The
small mouth opening of these patients also makes it difficult to
establish an airway. [29]
4.8. Urogenital features
The urogenital features described include hypospadias,
cryptorchidism, under descended testicles, cryptorchidism, and
amenorrhea.[9]
4.9. Immunological findings
De Silva and Bartsch described lymphopenia with reduced T- and
B-cell numbers. The in vitro functional immune deficits described
by De Silva et al[11] appeared more limited and, differently
from the results by Bartsch et al,[10] the pattern of immunoglob-
ulin (Ig) abnormalities was restricted to low IgG2 and IgG4
subclasses.
4.10. Fibroblast abnormalities
Mulvihill–Smith syndrome has similarities, such as onset in the
first decade, with other progeroid disorders [i.e., Hutchison–
Gilford, progeroid syndrome neonatal, Rothmund–Thompson
(OMIM number #268400), and Cockayne Syndrome A]. DNA
repair defects were demonstrated in Cockayne syndrome and
involved excision repair or the post-ultraviolet (post-UV) damage
replication pathway.[11] In 1975, Mulvihill and Smith[4]
demonstrated UV fibroblast sensitivity in their patient, while
the patient in the study by Ohashi et al[9] was reported to have X-
ray fibroblast sensitivity when compared with a healthy patient.
The patient described by De Silva et al[11] showed demonstrable
evidence of UV or X-ray fibroblast sensitivity; therefore, the
authors stated that these findings were not constant in Mulvihill–
Smith syndrome and did not provide evidence that DNA excision
repair pathway defects were involved in the pathogenesis of this
disorder.[11] Slow growth of cultured fibroblasts from patients
with Mulvihill–Smith syndrome was documented by Mulvihill
and Smith in 1975, Ohashi et al[9] in 1993, andDe Silva et al[11] in
1997. The distinctive differences in the fibroblasts from the
patient in the study by De Silva et al[11] compared with those by
Mulvihill and Smith and Ohashi et al[9] suggest that further
studies are needed in patients with this and other progeria-like
syndromes to identify if fibroblast abnormalities are a consistent
finding.
4.11. Sleep disorders
Sleep disorders were described in 3 cases by Yagihashi et al,[5]
Ferri et al,[12] and Lugaresi and Provini.[30] Clinical and
neurophysiological studies suggested that a particular sleep
disruption condition, which was in some ways similar to the sleep
alterations generally found in fibrillary chorea and fatal familial
insomnia by Morvan et al,[31] may be associated with Mulvihill–
Smith syndrome.[12,32–34] A mutation in the prion protein gene
(PRNP gene) causes the substitution of asparagine for aspartic
acid at codon 178, which in conjunction with methionine at
polymorphic codon 129, causes fatal familial insomnia.[35] The
patient reported by Ferri et al[12] had a cognitive status
characterized by progeria and early-onset dementia and showed
clinical traits that may have been due to similar genetic
alterations. More specifically, the patient’s sleep disruption,
called agrypnia excitata, was similar to that reported in people
suffering from fatal familial insomnia. For this reason, Ferri
et al[12] analyzed the PRNP gene; however, no mutations were
observed. Therefore, the clinical picture of their patient could not
be related to mutations in this gene and the genetic basis of
Mulvihill–Smith syndrome remains unknown.[12] Agrypnia
excitata has some peculiar polysomnographic findings, including
the complete loss of slow-wave sleep, the absence of sleep spindles
and K-complexes, and abnormal rapid eye movement sleep with
lack of muscle atonia.[5] Yagihashi et al[5] reported distinctive
sleep pattern features in their Japanese patient, including severe
insomnia with the marked disappearance of sleep spindles and K
complexes, loss of slow-wave sleep, and persisting muscle tone.
As the same sleep pattern abnormality was described by Ferri
et al,[12] Yagihashi et al[5] proposed that agrypnia excitata could
be a feature of Mulvihill–Smith syndrome.
4.12. Cognitive deterioration
Yagihashi et al[5] underlined that cognitive deterioration, in
addition to developmental delay, was an underappreciated
feature in patients with Mulvihill–Smith syndrome. Their
patient’s cognitive function started to decline when they were
26 years old, and at 28 years old they showed distinct cognitive
impairments resembling dementia, such as memory disorder,
executive dysfunction, and intellectual deficits. In 2005, Ferri
et al[12] also described the progressive decline in cognitive
function in a patient with Mulvihill–Smith syndrome aged 25
years. Yagihashi et al[5] suggested that cognitive deterioration,
severe insomnia accompanied by agrypnia excitata, and the early
onset of tumors could represent an emerging phenotype in adults
with Mulvihill–Smith syndrome.
5. Conclusion
The orofacial and dental features reported in Mulvihill–Smith
syndrome highlight the importance of special and early dental
care by a general dentist, orthodontist, oral surgeon, and
maxillofacial surgeon to reduce oral pathologies and lead to a
higher quality of life. All interventions should be strictly goal-
oriented, and the dental specialist must consider that dental
treatment is difficult, as these patients have a small oral aperture
and present potential anesthesia risks and other medical
disorders.[36] Intensive prophylaxis and goal-oriented intercep-
tive orthodontic and periodontal treatment produces better oral
health in patients with this progeria-like syndrome.
This literature review analyzing themedical and dental features
in patients withMulvihill–Smith syndrome may help clinicians to
diagnose this rare pathology. Dental abnormalities (i.e.,
hypodontia and taurodontism) and pigmented nevi on the face
could help clinicians to distinguish between Mulvihill–Smith
syndrome and other progeroid disorders.
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